Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7WVL

Structure of P4A2 Fab in complex with Spike-RBD from SARS-CoV-2

7WVL の概要
エントリーDOI10.2210/pdb7wvl/pdb
分子名称P4A2 Fab Light Chain, P4A2 Fab heavy chain, Spike protein S1, ... (4 entities in total)
機能のキーワードfab, spike-rbd, complex, antiviral protein, viral protein-immune system complex, viral protein/immune system
由来する生物種Mus musculus (Mouse)
詳細
タンパク質・核酸の鎖数3
化学式量合計71534.84
構造登録者
Narayanan, N.,Nair, D.T. (登録日: 2022-02-10, 公開日: 2022-12-07, 最終更新日: 2024-11-06)
主引用文献Parray, H.A.,Narayanan, N.,Garg, S.,Rizvi, Z.A.,Shrivastava, T.,Kushwaha, S.,Singh, J.,Murugavelu, P.,Anantharaj, A.,Mehdi, F.,Raj, N.,Singh, S.,Dandotiya, J.,Lukose, A.,Jamwal, D.,Kumar, S.,Chiranjivi, A.,Dhyani, S.,Mishra, N.,Kumar, S.,Jakhar, K.,Sonar, S.,Panchal, A.K.,Tripathy, M.R.,Chowdhury, S.R.,Ahmed, S.,Samal, S.,Mani, S.,Bhattacharyya, S.,Das, S.,Sinha, S.,Luthra, K.,Batra, G.,Sehgal, D.,Medigeshi, G.R.,Sharma, C.,Awasthi, A.,Garg, P.K.,Nair, D.T.,Kumar, R.
A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern.
Plos Pathog., 18:e1010994-e1010994, 2022
Cited by
PubMed Abstract: The emergence of new variants of SARS-CoV-2 necessitates unremitting efforts to discover novel therapeutic monoclonal antibodies (mAbs). Here, we report an extremely potent mAb named P4A2 that can neutralize all the circulating variants of concern (VOCs) with high efficiency, including the highly transmissible Omicron. The crystal structure of the P4A2 Fab:RBD complex revealed that the residues of the RBD that interact with P4A2 are a part of the ACE2-receptor-binding motif and are not mutated in any of the VOCs. The pan coronavirus pseudotyped neutralization assay confirmed that the P4A2 mAb is specific for SARS-CoV-2 and its VOCs. Passive administration of P4A2 to K18-hACE2 transgenic mice conferred protection, both prophylactically and therapeutically, against challenge with VOCs. Overall, our data shows that, the P4A2 mAb has immense therapeutic potential to neutralize the current circulating VOCs. Due to the overlap between the P4A2 epitope and ACE2 binding site on spike-RBD, P4A2 may also be highly effective against a number of future variants.
PubMed: 36508467
DOI: 10.1371/journal.ppat.1010994
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (3 Å)
構造検証レポート
Validation report summary of 7wvl
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon